Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment

Documenti analoghi

• Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity
  di: Jae Hyun Bae, et al.
  Pubblicazione: (2024)
• CEACAM1: Shielding the liver against fibrosis
  di: Kezhong Zhang
  Pubblicazione: (2024)
• Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction‐associated steatotic liver disease
  di: Carmen Arto, et al.
  Pubblicazione: (2024)
• Non‐linear relationship between liver fibrosis and femoral neck bone mineral density in metabolic dysfunction‐associated fatty liver disease patients with type 2 diabetes mellitus
  di: Jie Tao, et al.
  Pubblicazione: (2025)
• A weekly 4‐methylpyrazole treatment attenuates the development of non‐obese metabolic dysfunction‐associated steatotic liver disease (MASLD) in male mice: Role of JNK
  di: Katharina Burger, et al.
  Pubblicazione: (2024)